PV Reporter

03/02/2026

Tonight’s forecast. 100 percent chance of meat sweats. 🔥

Two steaks that clearly skipped leg day.

One sausage that got a little too close to the flame.

A glass of red supervising the operation. 🍷

Vegetables were invited.

They declined.

Medium rare. Slightly reckless. Fully committed.

My cardiologist just unfollowed me.😎🥩

Hope y'all had a great weekend!

02/20/2026

"Boss man" gave me permission to re-share this gem. 💎😉

Wishing everyone a safe, lovely weekend! 🌹

🩸 February is rare disease month

This cartoon shows red blood cells “gone wild,” a playful way to highlight a serious condition: Polycythemia Vera (PV).

In PV, the bone marrow produces too many red blood cells, and sometimes platelets and white blood cells. This can thicken the blood while raising the risk of clots, strokes, or other dangerous complications.

👉 Learn more and find trusted resources: https://www.pvreporter.com/

Feel free to share this post with your network.

Follow PV Reporter on Facebook for more resources and updates on MPNs.

02/19/2026

Thrombo-inflammatory endothelial signatures in JAK2-mutated myeloproliferative neoplasms (pre-print):

New research shows that in patients with Myeloproliferative Neoplasms (MPN), the lining of the blood vessels (the endothelium) is not just a passive bystander but an active driver of blood clots.

Scientists found that even though the vessels themselves do not carry the disease's primary "JAK2" mutation, they become hyper-reactive and "primed" for inflammation. This happens because the surrounding environment causes the vessel walls to release high levels of proteins that act like glue, making it much easier for life-threatening clots to form.

Essentially, the disease reprogrammed the genes of the blood vessels to be in a constant state of high alert, significantly increasing the risk of strokes and other complications.

https://www.biorxiv.org/content/10.64898/2026.02.16.706250v1

02/07/2026

Symptom-directed JAK inhibition remains standard, yet limited clonal selectivity underpins persistent progression, treatment discontinuation from intolerance, and waning spleen/symptom responses over time.

Emerging ultraprecision therapies target CALR mutations in myelofibrosis, promising more effective treatments and improved patient outcomes for pharmacists.

02/04/2026

Today is World Cancer Day 2026. 👇

Since 2013, we've been dedicated to helping MPN cancer patients live better lives. PV Reporter and MPN Cancer Connection provide the tools you need to become your own advocate, connect with MPN specialists, and access educational programs on emerging treatment options.

Led by founder David Wallace and our dedicated team, we bring a unique patient perspective to the MPN community, translating complex research into actionable information you can use.

01/30/2026

Partner Corner: PV In Focus – Fort Lauderdale

Join us for a day of community and education on polycythemia vera!

📍 Fort Lauderdale, FL
📅 February 28th, 2026
🕣 8:30 AM – 2:00 PM

Topics include:

- PV overview and treatment options
- A patient's perspective
- Self-advocacy
- Mental health

Breakfast and lunch provided.

Register at PVInFocus.com

01/27/2026

Ropeginterferon alfa-2b-njft recognized by National Comprehensive Cancer Network® (NCCN®) as recommended treatment option, listing it as a Category 1 preferred regimen for ET patients with inadequate response to or loss of response to existing treatments

Ropeginterferon alfa-2b-njft recognized by National Comprehensive Cancer Network® (NCCN®) as recommended treatment option, listing it as a Category 1 preferred regimen for ET patients with inadequate response to or loss of response to existing treatments BURLINGTON, Mass, Jan. 27, 2026–PharmaEss...

01/27/2026

Novartis hasn’t given up on its MorphoSys-originated BET inhibitor pelabresib, but it needs to carry out another phase 3 study before filing in the US – and details of that trial have just been listed on clinicaltrials.gov.

https://www.oncologypipeline.com/apexonco/novartis-perseveres-pelabresib

A new phase 3, Manifest-3, will start in April to support US filing.

01/16/2026

FDA decision on Rusfertide expected by Aug. 2026 according to this article 👇

Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development. Hundreds of millions of dollars are on the line.

01/16/2026

Interesting research - Scientists Identify Pre-Cancerous States in Seemingly Normal Aging Tissues

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

01/12/2026

New targeted treatment offers hope for people with myelofibrosis

https://www.scimex.org/newsfeed/new-targeted-treatment-offers-hope-for-people-with-myelofibrosis

01/06/2026

Big News for the Myelofibrosis Community! 📣

For a long time, many Myelofibrosis patients in the early stages have been told to "watch and wait." But a new 2025 study suggests that "acting early" might be the better path.

The study found that using Interferon early on can help reduce bone marrow scarring and lower the "burden" of the disease. This is a huge win for those looking for proactive ways to manage their health!

Check out the article to learn more about these findings:
👉 https://www.pvreporter.com/interferon-for-myelofibrosis-2025-study-challenges-watch-and-wait/

Early interferon treatment in pre-fibrotic myelofibrosis may slow disease progression, reduce fibrosis, and challenge the long-standing watch-and-wait approach.